Astrana Health, Inc. (ASTH) · Aug 6, 2026 · Company update

Profitability beat expectations and lifted the 2026 EBITDA floor

Profitability beat expectations and lifted the 2026 EBITDA floor

The quarter was better on earnings than on revenue. Published consensus called for roughly $0.34 of EPS and $985.6 million of revenue; Astrana delivered $0.40 of diluted GAAP EPS and $972.5 million of revenue. That is a modest EPS beat but a roughly 1% revenue shortfall versus the published estimate.

MetricQ2 2026Q2 2025 / expectation
Revenue$972.5M$654.8M; published expectation $985.6M
Diluted GAAP EPS$0.40$0.19; consensus $0.34
Adjusted EPS$0.80$0.55
Adjusted EBITDA$68.9M$48.1M; prior company guide $65M-$70M
Free cash flow, six months$92.9M$103.0M

Underlying profitability clearly outperformed the standing company bar. Adjusted EBITDA rose 43% year over year to $68.9 million, landing above the midpoint of the prior $65 million-$70 million quarterly guide, while adjusted EPS increased to $0.80 from $0.55. Revenue grew 49% to $972.5 million, but the adjusted EBITDA margin remained approximately 7%, so the earnings upside came more from scale and operating execution than from a major margin expansion. (Summary of Selected Financial Results; Reconciliation of Net Income to EBITDA and Adjusted EBITDA)

Management raised the quality of the full-year outlook, but not the growth top line. Full-year revenue guidance stayed at $3.8 billion-$4.1 billion and free-cash-flow guidance stayed at $105 million-$132.5 million. Adjusted EBITDA guidance moved from $250 million-$280 million to $255 million-$280 million, lifting only the low end by $5 million rather than raising the ceiling. That is a constructive revision, but it signals incremental confidence rather than a wholesale reset. (Guidance; Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA)

Cash generation was the main softer spot. Six-month operating cash flow fell to $100.8 million from $107.5 million, and free cash flow declined to $92.9 million from $103.0 million despite much higher earnings. Cash also fell to $400.8 million from $429.5 million at year-end, although debt repayment reduced long-term debt by roughly $102 million. The filing attributes no single definitive cause for the cash-flow decline, so the earnings beat does not yet translate into stronger year-to-date cash conversion. (Cash Flow statement; Balance Sheet Highlights)

Net read: a real but not dramatic positive surprise. The market received a modest GAAP EPS beat, an adjusted-earnings beat against the prior operating guide, and a higher EBITDA guidance floor. Those positives outweigh the small revenue miss and weaker cash conversion, while the unchanged revenue and free-cash-flow outlook limits how much the filing changes the broader 2026 picture.

Original filing on SEC EDGAR

More Astrana Health, Inc. news

Profitability beat expectations and lifted the 2026 EBITDA floor | ASTH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.